Novo Nordisk to Investigate Ozempic's Impact on Alcohol Consumption

New clinical trial will primarily assess liver health but also monitor changes in alcohol use, reflecting growing interest in GLP-1 drugs for diverse conditions.

• Novo Nordisk plans to study the effects of Ozempic on alcohol consumption in a new clinical trial.
• The trial will primarily focus on improving liver health but will also track changes in alcohol use.
• GLP-1 drugs like Ozempic and Wegovy have seen widespread use for diabetes, obesity, and now potentially for alcohol-related conditions.
• Lilly and Novo Nordisk dominate the GLP-1 market, with significant sales and ongoing expansion of manufacturing capabilities.
• Both companies are exploring broader applications for GLP-1 drugs, including treatments for heart disease, sleep apnea, and Alzheimer's.

3 Articles

CNN The Telegraph Forbes